News and Trends 1 Feb 2020 Cardior Pharmaceuticals’ Heart Failure Drug Shows Curative Potential German biotech company Cardior Pharmaceuticals’ candidate heart failure drug has the potential to stop the condition in its tracks, according to early studies in animal models. At present, treatments for heart failure, including ACE inhibitors, beta blockers, and diuretics, target the symptoms of the disease, such as high blood pressure, rather than the actual cause. […] February 1, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2019 Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease A treatment developed by the Irish company Amarin has become the first FDA-approved drug to lower the risk of strokes and heart attacks when combined with statins in patients with high levels of circulating fat molecules called triglycerides. To be eligible for Vascepa, patients must also either have established cardiovascular disease, or type 2 diabetes […] December 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2019 German Biotech Raises €7M Series A to Treat Acute Heart Failure 4TEEN4 Pharmaceuticals has raised a Series A round of €6.9M to fuel the development of a first-in-class antibody drug that could reduce mortality in acute heart failure. The round was led by Brandenburg Kapital, a subsidiary of the German investment bank Investitionsbank des Landes Brandenburg. Other investors in the round, including business angels and private […] December 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Sep 2019 Top Cardiology Biotech News from the ESC Conference 2019 Many cardiology companies and academics gathered in Paris earlier this week to showcase their latest research into cardiovascular diseases. Read on for a roundup of the most exciting cardiology news from the biotech scene. The European Society of Cardiology teamed up with the World Heart Federation this year to arrange a conference themed on global […] September 5, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2019 Anti-Aging Gene Therapy Treats Cardiovascular Disease in Mice A research group in Italy has reduced cardiovascular disease in mice by expressing an anti-aging gene often seen in centenarians. This could one day lead to a gene therapy treating the same condition in humans. Centenarians have long lives thanks to a mix of their environment, lifestyle, and their genes. In the past, researchers at […] July 10, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2019 Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […] July 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2019 Diagnostic Test Beats ‘Bad’ Cholesterol at Predicting Heart Attacks A study run by the Finnish diagnostics biotech Zora Biosciences has found two biomarkers that are better at predicting heart attacks and deaths in patients with coronary heart disease than the current gold standard — measuring ‘bad’ cholesterol in the blood. To assess the risk of death or heart attacks in people with coronary […] June 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 16 Apr 2019 Researchers in Israel 3D Print a Personalized Heart from Donor’s Tissue A group of scientists in Israel is the first to 3D print a vascularized heart using reprogrammed cells and biological material from a donor. The technology could one day provide printed hearts for transplants with low risks of rejection by a patient’s immune system. Organ bioprinting is a technique similar to 3D printing where you […] April 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 4 Mar 2019 Swiss Biotech Raises €8.8M to Progress Regenerative Stroke Treatment The Swiss company NovaGo has raised €8.8M (CHF 10M) in Series A funding to develop one of the first therapies to help the nervous system regenerate after a stroke. Novago develops antibodies that inhibit Nogo-A, a key molecule that stops nerve cells from growing new connections in the adult brain and spinal cord. This lets […] March 4, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Dec 2018 Novo Nordisk Partners Dutch Biotech to Prevent Cardiovascular Disease Novo Nordisk and the Dutch company Staten Biotechnology will partner to develop a treatment to remove excess fatty molecules called triglycerides from the blood, high levels of which increase a person’s risk for cardiovascular disease. Novo has agreed to pay up to €430M for the worldwide rights to Staten’s candidate drug, as well as the exclusive […] December 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Nov 2018 French Company’s Drug Lowers Blood Pressure by Targeting Brain Proteins The French company Quantum Genomics is developing a first-in-class drug that targets proteins in the brain to lower blood pressure. A Phase IIb trial, run by Quantum Genomics, found that eight weeks of taking its drug significantly lowered blood pressure in patients who were overweight or obese and with high blood pressure. This reduction also […] November 13, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2018 Series C Bags German Company €17M for Irregular Heartbeat Treatment Omeicos Therapeutics has secured €17M in a Series C round to fund clinical development of its lead treatment for irregular heartbeat. Robert Fischer, CEO of the German biopharmaceutical company, told me that getting the attention of investors such as the Dutch company Forbion, which led the round, was just as helpful as the money itself. […] November 5, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email